Flutiform failure in Phase III COPD trial a setback for Mundipharma and Vectura

The UK’s pharma company Mundipharma and inhaled therapies developer Vectura (LSE: VEC) said that Flutiform has failed to meet the primary endpoint of a Phase III trial in chronic obstructive pulmonary disease (COPD).

Vectura’s share price dropped by almost 9% on Tuesday as the news was announced that the trial had failed to meet the goal of demonstrating statistically significant superiority in the reduction of annualised rates of moderate and severe COPD exacerbations when compared to mono-component long-acting beta-agonists (LABA) treatment alone.

Mundipharma carried out this Phase III study to support a filing to expand the approved indication for the regular treatment of asthma of Flutiform in Europe to include COPD, and is now analyzing the trial’s other endpoints.